Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin
Notwithstanding the study's limited sample size and observational nature, Switching to EFG yielded notable therapeutic benefits compared with IVIG, while additionally reducing the hospitalization rate and enhancing QOL. Therefore, EFG may be a valuable outpatient treatment option for refractory MG.
Authors
- Genya Watanabe (ORCID: https://orcid.org/0000-0001-8444-6525)
- Aki Yasaka
- Kenichi Tsukita
- Go Akao
- Amane Ishikawa
- Ayane Tamagake
- Chihiro Sasaki
- Moeko Saito
- Yasushi Suzuki
Institutions
- Sendai Medical Center (JP)
- Miyagi Prefecture Sendai Higashi High School (JP)
Publication Details
- Journal
- Clinical Neurology and Neurosurgery
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1016/j.clineuro.2026.109389
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00